Comment from TerSera Therapeutics LLC

Summary: TerSera Therapeutics LLC, the holder of the NDA for Prialt (ziconotide), opposes the nomination of ziconotide to the 503B Bulk Drug Substance List. They argue that the proposed compounded products pose significant safety risks, lack a demonstrated clinical need, and do not offer any advantages over the existing FDA-approved formulation.